Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-altitude illness.

Buddha Basnyat1, David R Murdoch

  • 1Nepal International Clinic, Kathmandu, Nepal; Himalayan Rescue Association, Kathmandu, Nepal. rishibas@wlink.com.np <rishibas@wlink.com.np>

Lancet (London, England)
|June 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expecting the unexpected: the next outbreak will not necessarily look like the last.

The New Zealand medical journal·2026
Same author

Global estimates of mortality in newborn babies, children, and adolescents.

BMJ (Clinical research ed.)·2026
Same author

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational data.

Vaccine·2026
Same author

Correction: Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.

PLoS neglected tropical diseases·2026
Same author

Case Report: Multi drug resistant tuberculosis in an 18-month-old boy with seizure, vomiting, and loss of vision.

Wellcome open research·2025
Same author

Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.

PLoS neglected tropical diseases·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

High-altitude illness, including AMS, HACE, and HAPE, has complex causes not fully understood. Gradual ascent and acetazolamide are key prevention strategies, with future research promising more insights.

Area of Science:

  • Altitude Medicine
  • Physiology
  • Pathophysiology

Background:

  • High-altitude illness encompasses acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE).
  • Current understanding of pathophysiology is incomplete, particularly regarding brain swelling in AMS/HACE and pulmonary hypertension in HAPE.
  • Limited data exists on the genetic basis of susceptibility to high-altitude illness.

Purpose of the Study:

  • To review the current understanding of high-altitude illness pathophysiology.
  • To discuss prevention strategies and pharmacological interventions.
  • To highlight areas for future research.

Main Methods:

  • Literature review of existing studies on high-altitude illness.
  • Synthesis of current knowledge on mechanisms, genetics, and prevention.

Related Experiment Videos

  • Identification of knowledge gaps and future research directions.

    • Main Results:

    • Key areas of understanding include brain swelling mechanisms in AMS/HACE and pulmonary hypertension in HAPE.
    • Inflammation and alveolar fluid clearance are implicated in HAPE.
    • Gradual ascent is the primary prevention method; acetazolamide is the preferred chemoprophylaxis for AMS.

    Conclusions:

    • Further research is needed to fully elucidate the pathophysiology and genetic basis of high-altitude illness.
    • Gradual acclimatization remains the most effective prevention strategy.
    • Acetazolamide is the recommended pharmacological agent for AMS prevention, with ongoing research into other treatments.